by Ashwin Kulkarni | Jul 28, 2023 | New
miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. miRecule’s DREAmiR™ discovery platform, combined with Sanofi’s Nanobody® technology, enables the...
by Ashwin Kulkarni | Oct 4, 2022 | New
Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create a groundbreaking treatment for FSHD miRecule will receive an upfront payment with potential future milestone payments of nearly $400...
by Ashwin Kulkarni | Sep 30, 2022 | New
Read the press release here: SOLVE-FSHD Invests US 1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA-Conjugate to Treat Facioscapulohumeral Muscular...
by Ashwin Kulkarni | Feb 28, 2022 | Archived
Gaithersburg, Md., February 28, 2022 – miRecule, Inc. today announces it has won a joint Maryland Industrial Partnerships (MIPS) grant in collaboration with Dr. Robert Bloch at the University of Maryland, Baltimore for $100,000. This collaborative partnership is...
by Ashwin Kulkarni | Jun 8, 2021 | Archived
Gaithersburg, MD (June 8, 2021) – miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An Kang, Ph.D. to serve as its Vice President of Research. Dr. Kang joins miRecule...
